Simon J Fisher1, Xingyue Huang2, Manjiri Pawaskar3, Edward A Witt4, Swapnil Rajpathak2, R Ravi Shankar2, Silvio E Inzucchi5. 1. Department of Medicine, Division of Endocrinology, University of Utah, 15N 2030 E, EIHG Room 2110, Salt Lake City, UT, 84112, USA. 2. Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA. 3. Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA. Manjiri.Pawaskar@merck.com. 4. Kantar Health, 11 Madison Ave. #12, New York, NY, 10010, USA. 5. Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Abstract
PURPOSE: The aim of the current study is to assess the patient and physician experience and knowledge of hypoglycemia in the management of type 2 diabetes (T2DM). METHODS: T2DM patients (N = 1002) completed questionnaires on hypoglycemia experience, familiarity, and fear. Their responses were compared across various antihyperglycemic treatment regimens; specifically, (1) insulin only or insulin combined with sulfonylurea [SU] and/or metformin, (2) SU only with/without metformin, and (3) neither insulin nor SU. Physicians (N = 1003) completed questionnaires on hypoglycemia knowledge and decision-making, and their responses were compared by specialty [75% primary care providers (PCPs) and 25% endocrinologists]. RESULTS: T2DM patients treated with, (1) insulin only, or (2) insulin plus SU or metformin, reported the most experience and familiarity with-but also fear of-hypoglycemic events. Insulin-treated patients (insulin alone or insulin plus SU/metformin) also reported experiencing more hypoglycemia (all p-values <0.012). For physicians, endocrinology specialty was significantly associated with higher hypoglycemia knowledge scores (all p-values <.001). Irrespective of specialty, physician hypoglycemia knowledge, in turn, was associated with correct treatment decision-making (all p-values <0.001). CONCLUSIONS: Insulin-based antihyperglycemic regimens were associated with high prevalence, severity, familiarity, and fear of hypoglycemia. An effective strategy to mitigate the burden of hypoglycemia may be to optimize pharmacological therapy to prevent these events. Since physician hypoglycemia knowledge was highly correlated to correct therapeutic decision-making, continued physician education regarding this acute complication of diabetes treatment should be prioritized for those managing patients with T2DM.
PURPOSE: The aim of the current study is to assess the patient and physician experience and knowledge of hypoglycemia in the management of type 2 diabetes (T2DM). METHODS: T2DM patients (N = 1002) completed questionnaires on hypoglycemia experience, familiarity, and fear. Their responses were compared across various antihyperglycemic treatment regimens; specifically, (1) insulin only or insulin combined with sulfonylurea [SU] and/or metformin, (2) SU only with/without metformin, and (3) neither insulin nor SU. Physicians (N = 1003) completed questionnaires on hypoglycemia knowledge and decision-making, and their responses were compared by specialty [75% primary care providers (PCPs) and 25% endocrinologists]. RESULTS: T2DM patients treated with, (1) insulin only, or (2) insulin plus SU or metformin, reported the most experience and familiarity with-but also fear of-hypoglycemic events. Insulin-treated patients (insulin alone or insulin plus SU/metformin) also reported experiencing more hypoglycemia (all p-values <0.012). For physicians, endocrinology specialty was significantly associated with higher hypoglycemia knowledge scores (all p-values <.001). Irrespective of specialty, physician hypoglycemia knowledge, in turn, was associated with correct treatment decision-making (all p-values <0.001). CONCLUSIONS:Insulin-based antihyperglycemic regimens were associated with high prevalence, severity, familiarity, and fear of hypoglycemia. An effective strategy to mitigate the burden of hypoglycemia may be to optimize pharmacological therapy to prevent these events. Since physician hypoglycemia knowledge was highly correlated to correct therapeutic decision-making, continued physician education regarding this acute complication of diabetes treatment should be prioritized for those managing patients with T2DM.
Authors: L A Donnelly; A D Morris; B M Frier; J D Ellis; P T Donnan; R Durrant; M M Band; G Reekie; G P Leese Journal: Diabet Med Date: 2005-06 Impact factor: 4.359
Authors: Janice Ms Lopez; Kathy Annunziata; Robert A Bailey; Marcia Ft Rupnow; Donald E Morisky Journal: Patient Prefer Adherence Date: 2014-05-08 Impact factor: 2.711
Authors: Jan Brož; Denisa Janíčková Žďárská; Jana Urbanová; Marek Brabec; Viera Doničová; Radka Štěpánová; Emil Martinka; Milan Kvapil Journal: Diabetes Ther Date: 2018-08-09 Impact factor: 2.945